文献速递肿瘤 PET/CT放射性药物与辐射防护

左旋门冬酰胺酶化疗后皮下白脂肪FDG分布改变

Altered FDG Biodistribution in Subcutaneous White Fat on PET/CT Following l-Asparaginase Chemotherapy.
PubMed 文献 · Clin Nucl Med · 2021-01-01

一例13岁纵隔T细胞淋巴母细胞淋巴瘤男孩,在 interim 治疗后FDG PET/CT中表现为皮下白脂肪组织弥漫性摄取增高、内脏摄取减低。该分布改变归因于PET/CT前3小时给予化疗酶左旋门冬酰胺酶,影响脂肪细胞氨基酸和葡萄糖代谢,并干扰了治疗反应评估。

要点

  • 左旋门冬酰胺酶给药后3小时内行FDG PET/CT可致皮下白脂肪弥漫摄取、内脏摄取减低。
  • 该分布改变会干扰淋巴瘤治疗反应评估,应尽量延长化疗与PET/CT间隔。
  • 体外脂肪细胞可保护白血病细胞免受左旋门冬酰胺酶作用,提示该分布改变或与耐药相关。

核心结论

  • 左旋门冬酰胺酶化疗后短期内行FDG PET/CT可出现皮下白脂肪弥漫性摄取增高和内脏摄取减低的分布改变,并负面影响治疗反应评估。

研究设计与样本

  • 单例13岁纵隔T细胞淋巴母细胞淋巴瘤男孩的病例观察,于 interim 治疗后行FDG PET/CT。

主要发现

  • FDG PET/CT显示皮下白脂肪组织弥漫性活性增高、内脏活性减低。
  • 该分布改变归因于PET/CT前3小时给予左旋门冬酰胺酶,影响脂肪细胞氨基酸和葡萄糖代谢。
  • 治疗反应评估受到该分布改变的不利影响。

临床怎么用

  • 在连续肿瘤治疗周期中,应尽量延长化疗与PET/CT之间的时间间隔。

局限性

  • 仅为单例病例观察,未提供样本量、统计检验或可推广的阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 13-year-old boy with mediastinal T-cell lymphoblastic lymphoma demonstrated an altered biodistribution with diffuse activity in subcutaneous white adipose tissue and decreased visceral activity on interim posttreatment FDG PET/CT. This altered biodistribution was attributed to administration of the chemotherapeutic enzyme l-asparaginase 3 hours preceding the PET/CT, altering adipocytes amino acid and glucose metabolism. Treatment response assessment was adversely affected by the altered biodistribution, emphasizing the importance of maximizing the time between chemotherapy and PET/CT during successive oncologic treatment cycles. Because adipocytes protect leukemic cells in culture from l-asparaginase, we hypothesize that white adipose tissue-altered biodistribution may be related to l-asparaginase resistance.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Young CR, Kulon ME, Boustani AM, et al. Altered FDG Biodistribution in Subcutaneous White Fat on PET/CT Following l-Asparaginase Chemotherapy. Clin Nucl Med. 2021. PMID: 33086270. doi:10.1097/RLU.0000000000003340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。